Parathyroid Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRT010 MIFTS: 64	Parathyroid Carcinoma Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Parathyroid Carcinoma

MalaCards integrated aliases for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma ⁵⁷ ¹² ⁵³ ²⁵ ⁵⁹ ⁷⁵ ³⁷ ²⁹ ¹³ ⁵⁵ ⁶ ¹⁵

Parathyroid Neoplasms ²⁵ ⁵⁵ ⁴⁴ ⁷³

Parathyroid Cancer ⁷⁶ ⁵³ ²⁵ ⁵⁵

Malignant Tumor of Parathyroid Gland ¹² ²⁵ ⁷³

Malignant Neoplasm of Parathyroid Gland ¹² ²⁵

Neoplasm of the Parathyroid Gland ²⁹ ⁶

Parathyroid Gland Adenocarcinoma ¹² ⁷³

Carcinoma of Parathyroid Gland ¹² ²⁵

Parathyroid Gland Cancer ¹² ²⁵

Parathyroid Neoplasm ¹² ⁷⁶

Prtc ⁵⁷ ⁷⁵

Malignant Neoplasm of the Parathyroid ¹²

Malignant Parathyroid Gland Neoplasm ²⁵

Malignant Neoplasm of Parathyroid ²⁵

Malignant Parathyroid Gland Tumor ²⁵

Cancer of the Parathyroid Gland ²⁵

Malignant Parathyroid Neoplasm ²⁵

Malignant Tumor of Parathyroid ²⁵

Neoplasm of Parathyroid Gland ¹²

Malignant Parathyroid Tumor ²⁵

Parathyroid Gland Carcinoma ²⁵

Parathyroid Gland Neoplasm ¹²

Parathyroid Adenocarcinoma ²⁵

Cancer of the Parathyroid ²⁵

Carcinoma, Parathyroid ⁴⁰

Characteristics:

Orphanet epidemiological data:

⁵⁹

parathyroid carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adult; Age of death: adult,elderly;

HPO:

³²

parathyroid carcinoma:
Inheritance somatic mutation autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³⁴

Neoplasms

Malignant neoplasms of thyroid and other endocrine glands

Malignant neoplasm of other endocrine glands and related structures

Malignant neoplasm: Parathyroid gland

Orphanet: ⁵⁹

Rare endocrine diseases

External Ids:

OMIM ⁵⁷ 608266

Disease Ontology ¹² DOID:1540

ICD10 ³³ C75.0

ICD9CM ³⁵ 194.1

MeSH ⁴⁴ D010282

NCIt ⁵⁰ C3313 C4906 C9322

SNOMED-CT ⁶⁸ 127020005 255037004 363481002 more

Orphanet ⁵⁹ ORPHA143

UMLS via Orphanet ⁷⁴ C0687150

ICD10 via Orphanet ³⁴ C75.0

MedGen ⁴² C0687150

KEGG ³⁷ H01558

SNOMED-CT via HPO ⁶⁹ 263681008 236423003 42399005 more

UMLS ⁷³ C0030521 C0153653 C0687150

Sources

Summaries for Parathyroid Carcinoma

NIH Rare Diseases : ⁵³ The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 143Disease definitionParathyroid carcinoma (PRTC) is a very rare, slow-growing, clinically serious endocrine tumor that generally develops in mid-adulthood. PRTC presents as a palpable painless mass in the neck and causes severe hypercalcemia and related symptoms, non-specific gastrointestinal manifestations, as well as renal and bone complications related to primary hyperparathyroidism (nephrolithiasis, impaired renal function, osteoporosis, bone pain, and pathologic fractures, etc.). Some PRTCs are however non-functioning tumors.Visit the Orphanet disease page for more resources.

MalaCards based summary : Parathyroid Carcinoma, also known as parathyroid neoplasms, is related to osteitis fibrosa and secondary hyperparathyroidism of renal origin. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways are Neuroscience and Hepatitis C and Hepatocellular Carcinoma. The drugs Sensipar and Calcimimetic Agents have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and lung, and related phenotypes are muscle weakness and dysphagia

Disease Ontology : ¹² An endocrine gland cancer located in the parathyroid glands located in the neck.

Genetics Home Reference : ²⁵ Parathyroid cancer is a rare cancer that usually affects people in their forties or fifties and occurs in one of the four parathyroid glands. The parathyroid glands are located in the neck and secrete parathyroid hormone, which enhances the release of calcium into the blood.

UniProtKB/Swiss-Prot : ⁷⁵ Parathyroid carcinoma: These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

Wikipedia : ⁷⁶ Parathyroid carcinoma is a rare malignant neoplasm resulting in parathyroid adenoma to carcinoma... more...

Description from OMIM: 608266

Sources

Related Diseases for Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)

#	Related Disease	Score	Top Affiliating Genes
1	osteitis fibrosa	31.6	CALCA CASR PTH
2	secondary hyperparathyroidism of renal origin	29.8	CALCA CASR PTH
3	hyperparathyroidism 2 with jaw tumors	29.7	CASR CCND1 CDC73 MEN1 RET
4	thyroiditis	29.5	CALCA RET
5	bone disease	29.4	CALCA CASR PTH
6	multiple endocrine neoplasia	29.2	CALCA MEN1 RET
7	adenoma	28.2	CASR CCND1 CDC73 MEN1 RET
8	thyroid cancer	28.1	CALCA CCND1 LGALS3 RET
9	hyperparathyroidism	27.9	CALCA CASR CDC73 MEN1 PTH RET
10	multiple endocrine neoplasia, type i	27.8	CASR CDC73 MEN1 PTH RET
11	multiple endocrine neoplasia, type iia	27.3	CALCA CDC73 MEN1 PTH RET
12	primary hyperparathyroidism	26.9	CALCA CASR CCND1 CDC73 MEN1 PTH
13	parathyroid adenoma	26.8	CALCA CASR CCND1 CDC73 MEN1 PTH
14	parathyroid cancer, childhood	12.0
15	fibrogenesis imperfecta ossium	10.5	CALCA PTH
16	hypocalciuric hypercalcemia, familial, type iii	10.5	CASR PTH
17	hypoparathyroidism, familial isolated	10.5	CASR PTH
18	calciphylaxis	10.5	CASR PTH
19	hypocalcemia, autosomal dominant 1	10.4	CALCA CASR
20	hypophosphatasia, adult	10.4	CALCA PTH
21	hypocalciuric hypercalcemia, familial, type ii	10.4	CASR PTH
22	burn scar	10.4	CALCA UCHL1
23	cloacogenic carcinoma	10.4	CALCA PTH
24	phosphorus metabolism disease	10.4	CASR PTH
25	glucocorticoid-induced osteoporosis	10.4	CALCA PTH
26	metaphyseal chondrodysplasia, jansen type	10.3	CALCA PTH
27	thyroid gland disease	10.3	CALCA PTH
28	bone resorption disease	10.2	CALCA PTH
29	familial hypocalciuric hypercalcemia	10.2	CASR CDC73 PTH
30	mediastinitis	10.2
31	hypercalcemia, infantile, 1	10.2	CALCA CASR PTH
32	hyperphosphatemia	10.1	CASR PTH
33	lichen nitidus	10.1	RET UCHL1
34	renal osteodystrophy	10.1	CALCA CASR PTH
35	mineral metabolism disease	10.1	CALCA CASR PTH
36	bone remodeling disease	10.1	CALCA PTH
37	hyperparathyroidism 3	10.1	CDC73 MEN1
38	osteomalacia	10.1	CALCA CASR
39	chronic kidney failure	10.1	CALCA CASR PTH
40	hyperparathyroidism 1	10.1	CDC73 MEN1
41	pancreatic somatostatinoma	10.0	CALCA MEN1
42	malignant struma ovarii	10.0	LGALS3 RET
43	parathyroid transitional clear cell adenoma	10.0	MEN1 PTH
44	polymorphous low-grade adenocarcinoma	10.0	CCND1 LGALS3
45	pancreatic cholera	10.0	CALCA MEN1
46	periodontitis	9.9
47	endotheliitis	9.9
48	colonic disease	9.9	RET UCHL1
49	clear cell adenoma	9.9	MEN1 PTH
50	carcinoid syndrome	9.9	CALCA MEN1

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):

Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:

Sources

Symptoms & Phenotypes for Parathyroid Carcinoma

Clinical features from OMIM:

608266

Human phenotypes related to Parathyroid Carcinoma:

⁵⁹ ³² (show all 38)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	muscle weakness ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0001324
2	dysphagia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0002015
3	nausea and vomiting ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002017
4	constipation ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002019
5	renal insufficiency ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000083
6	polydipsia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001959
7	hypophosphatemia ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0002148
8	fatigue ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0012378
9	osteoporosis ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0000939
10	weight loss ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001824
11	pancreatitis ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0001733
12	hypercalciuria ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0002150
13	fibroma ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0010614
14	nephrocalcinosis ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0000121
15	nephrolithiasis ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0000787
16	hypercalcemia ⁵⁹ ³²		Obligate (100%)	HP:0003072
17	elevated circulating parathyroid hormone level ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0003165
18	episodic abdominal pain ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002574
19	peptic ulcer ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0004398
20	bone pain ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002653
21	hoarse voice ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001609
22	headache ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002315
23	pancreatic adenocarcinoma ⁵⁹ ³²	very rare (1%)	Very rare (<4-1%)	HP:0006725
24	lipoma ⁵⁹ ³²	very rare (1%)	Very rare (<4-1%)	HP:0012032
25	testicular neoplasm ⁵⁹ ³²	very rare (1%)	Very rare (<4-1%)	HP:0010788
26	chondrocalcinosis ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000934
27	nephroblastoma ⁵⁹ ³²	very rare (1%)	Very rare (<4-1%)	HP:0002667
28	thyroid carcinoma ⁵⁹ ³²	very rare (1%)	Very rare (<4-1%)	HP:0002890
29	renal cyst ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0000107
30	uterine leiomyoma ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0000131
31	parathyroid carcinoma ⁵⁹ ³²	obligate (100%)	Obligate (100%)	HP:0006780
32	infantile hypercalcemia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0008250
33	primary hyperparathyroidism ⁵⁹ ³²	obligate (100%)	Obligate (100%)	HP:0008200
34	shortened qt interval ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0012232
35	renal hamartoma ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0008696
36	mandibular pain ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0200025
37	hyperparathyroidism ³²			HP:0000843
38	abnormality of the parathyroid morphology ⁵⁹		Very frequent (99-80%)

MGI Mouse Phenotypes related to Parathyroid Carcinoma:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.08	PTH RET UCHL1 CCND1 CDC73 LGALS3
2	cellular	MP:0005384	10.07	CASR CCND1 CDC73 LGALS3 MEN1 PTH
3	digestive/alimentary	MP:0005381	10.05	CASR CCND1 CDC73 LGALS3 MEN1 RET
4	homeostasis/metabolism	MP:0005376	10.03	CASR CCND1 CDC73 LGALS3 MEN1 PTH
5	growth/size/body region	MP:0005378	10.02	CASR CCND1 CDC73 MEN1 PTH RET
6	hematopoietic system	MP:0005397	10	PTH RET UCHL1 CASR CCND1 CDC73
7	endocrine/exocrine gland	MP:0005379	9.97	CASR CCND1 CDC73 MEN1 PTH RET
8	immune system	MP:0005387	9.95	CASR CCND1 CDC73 LGALS3 MEN1 PTH
9	mortality/aging	MP:0010768	9.92	CASR CCND1 CDC73 LGALS3 MEN1 PTH
10	integument	MP:0010771	9.77	CASR CCND1 CDC73 LGALS3 UCHL1
11	neoplasm	MP:0002006	9.65	CCND1 CDC73 LGALS3 MEN1 RET
12	renal/urinary system	MP:0005367	9.55	CDC73 LGALS3 RET UCHL1 CASR
13	respiratory system	MP:0005388	9.35	CCND1 CDC73 LGALS3 RET UCHL1
14	skeleton	MP:0005390	9.1	CASR CCND1 CDC73 LGALS3 PTH UCHL1

Sources

Drugs & Therapeutics for Parathyroid Carcinoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Sensipar ¹⁸	CINACALCET HYDROCHLORIDE	Amgen	March 2004
FDA Label: Sensipar Disease/s that Drug Treats:Hyperparathyroidism / Hypercalcemia Indications and Usage: ¹⁸ Sensipar is a calcium-sensing receptor agonist indicated for: concentration time curve) is increased in patients with moderate and Secondary Hyperparathyroidism (HPT) in adult patients with chronic severe hepatic impairment. Patients should be closely monitored forkidney disease (CKD) on dialysis. (1.1) serum calcium, serum phosphorus, and iPTH levels throughout Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). (1.2) treatment. (5.3, 8.7) Hypercalcemia in adult patients with primary HPT for whomparathyroidectomy would be indicated on the basis of serum calciumlevels, but who are unable to undergo parathyroidectomy. (1.3) DrugBank Targets: ¹⁶ 1. Extracellular calcium-sensing receptor Mechanism of Action: ¹⁸ Target: calcium-sensing receptor Action: increases sensitivity to activation by extracellular calcium FDA: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulatorof PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, directly lowers PTH levels byincreasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH isassociated with a concomitant decrease in serum calcium levels.

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Calcimimetic Agents

Phase 4,Phase 3

Cinacalcet Hydrochloride

Phase 4,Phase 3

Hormone Antagonists

Phase 4,Phase 3

Hormones

Phase 4,Phase 3

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3

Indinavir

Approved

Phase 2

150378-17-9

5362440

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

nivolumab

Approved

Phase 2

946414-94-4

Anti-HIV Agents

Phase 2

Anti-Infective Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Antiviral Agents

Phase 2

Cytochrome P-450 CYP3A Inhibitors

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

HIV Protease Inhibitors

Phase 2

Liver Extracts

Phase 2,Phase 1

protease inhibitors

Phase 2

Antibodies

Phase 2

Antibodies, Monoclonal

Phase 2

Immunoglobulins

Phase 2

Cola

Nutraceutical

Phase 2,Phase 1

Bortezomib

Approved, Investigational

Phase 1

179324-69-7

387447 93860

Dacarbazine

Approved, Investigational

Phase 1

4342-03-4

5351166

Carboplatin

Approved

Phase 1

41575-94-4

10339178 498142 38904

Paclitaxel

Approved, Vet_approved

Phase 1

33069-62-4

36314

Trastuzumab

Approved, Investigational

Phase 1

180288-69-1

9903

Pancreatic Polypeptide

Investigational

Phase 1

59763-91-6

tipifarnib

Investigational

Phase 1

192185-72-1

159324

Entinostat

Investigational

Phase 1

209783-80-2

Adjuvants, Immunologic

Phase 1

Albumin-Bound Paclitaxel

Phase 1

Angiogenesis Inhibitors

Phase 1

Angiogenesis Modulating Agents

Phase 1

Antimitotic Agents

Phase 1

Antineoplastic Agents, Phytogenic

Phase 1

Interleukin-12

Phase 1

Histone Deacetylase Inhibitors

Phase 1

Gefitinib

Approved, Investigational

Not Applicable

184475-35-2

123631

Protein Kinase Inhibitors

Not Applicable

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer	Completed	NCT00037518	Phase 4	AMG 073
2	An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Completed	NCT01460030	Phase 3	Cinacalcet HCl
3	Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Recruiting	NCT03280264	Phase 3	KHK7580
4	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
5	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
6	Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Completed	NCT00580320	Phase 1	Dacarbazine and bortezomib
7	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Completed	NCT00004074	Phase 1
8	NGR-TNF in Treating Patients With Advanced Solid Tumors	Completed	NCT00098943	Phase 1
9	Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	Completed	NCT00005842	Phase 1	tipifarnib
10	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	NCT00020579	Phase 1	entinostat
11	Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior	Completed	NCT03046524
12	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	Completed	NCT00068497	Not Applicable	gefitinib

Search NIH Clinical Center for Parathyroid Carcinoma

Cochrane evidence based reviews: parathyroid neoplasms

Sources

Genetic Tests for Parathyroid Carcinoma

Genetic tests related to Parathyroid Carcinoma:

#	Genetic test	Affiliating Genes
1	Parathyroid Carcinoma ²⁹	CDC73
2	Neoplasm of the Parathyroid Gland ²⁹

Sources

Anatomical Context for Parathyroid Carcinoma

MalaCards organs/tissues related to Parathyroid Carcinoma:

⁴¹

Bone, Thyroid, Lung, Brain, Liver, Lymph Node, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Carcinoma:

¹⁹

The Parathyroid Gl

Sources

Publications for Parathyroid Carcinoma

Articles related to Parathyroid Carcinoma:

(show top 50) (show all 561)

#	Title	Authors	Year
1	Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review. ( 29922966 )	Di Meo G....Testini M.	2018
2	Subchondral Bone Restoration of Supra-acetabular Brown Tumor Secondary to Parathyroid Carcinoma: A Case Report. ( 29896462 )	Park Y.J....Ko J.W.	2018
3	Verification of candidate microRNA markers for parathyroid carcinoma. ( 29453660 )	Hu Y....Zhao Y.	2018
4	Role of calcium-sensing receptor, Galectin-3, Cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma. ( 29567879 )	Sungu N....A8akir B.	2018
5	The use of PET/CT in pregnancy: A case report of malignant parathyroid carcinoma and a review of the literature. ( 29636815 )	Gill M.M....Khurana R.	2018
6	Parathyroid carcinoma: From a case report to a review of the literature. ( 29353223 )	Fernandes J.M.P....Moreira da Costa A.	2018
7	Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma. ( 29971678 )	Lo W.M....Patel D.T.	2018
8	Cytological challenges in the diagnosis of intrathyroidal parathyroid carcinoma: A case report and review of literature. ( 29076656 )	Balakrishnan M....Kapila K.	2018
9	Nonfunctioning parathyroid carcinoma associated with parathyromatosis. A case report. ( 29631411 )	BartoA8ovA! L....Kodet R.	2018
10	An Unusual Case of Meningioma Showing Increased CaSR Expression with Parathyroid Carcinoma. ( 29388399 )	Yoo J.S....Chung C.H.	2018
11	The diagnostic accuracy of neck ultrasound, 4D-Computed tomographyand sestamibi imaging in parathyroid carcinoma. ( 28987702 )	Christakis I....Perrier N.D.	2017
12	Simultaneous Incidental Parathyroid Carcinoma and Intrathyroid Parathyroid Gland in Suspected Renal Failure Induced Hyperparathyroidism. ( 28825015 )	Pappa A....Hackman T.	2017
13	[Parathyroid carcinoma: about a case and review of the literature]. ( 28819506 )	Kolsi N....Koubaa J.	2017
14	Hypercalcaemic encephalopathy due to metastatic parathyroid carcinoma. ( 28566413 )	Sadacharan D....Rakeshchandru K.	2017
15	Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. ( 28458892 )	Rozhinskaya L....Dedov I.	2017
16	Parathyroid carcinoma: an unusual presentation of a rare neoplasm. ( 29354025 )	Shruti S....Siraj F.	2017
17	A role for TET2 in parathyroid carcinoma. ( 28642344 )	Barazeghi E....Westin G.	2017
18	Synchronous parathyroid carcinoma and papillary thyroid carcinoma in a patient with long-standing schizophrenia. ( 29032667 )	Baek C.O....Song S.K.	2017
19	Pathological bone fractures in a patient with parathyroid carcinoma - A Case Report. ( 29256556 )	Shahid A....Iftikhar F.	2017
20	Giant parathyroid adenoma: differential aspects compared to parathyroid carcinoma. ( 28491324 )	Araujo Castro M....GarcA-a N.P.	2017
21	<i>MEN1</i> gene mutation with parathyroid carcinoma: first report of a familial case. ( 29097378 )	Cinque L....Guarnieri V.	2017
22	Parathyroid carcinoma in a patient with three prior parathyroid adenomas. ( 28636744 )	Goldenberg M....Bann D.V.	2017
23	Super Scan Caused by Parathyroid Carcinoma Observed Both in<sup>18</sup>F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy. ( 28976334 )	GA1ney A.^.B....BallA+ H.T.	2017
24	Denosumab as a long-term palliative therapy in parathyroid carcinoma. ( 28011854 )	Tong C.V....Hussein Z.	2017
25	Parathyroid carcinoma: a clinical and genetic perspective. ( 28949121 )	Cetani F....Marcocci C.	2017
26	Atypical manifestation of parathyroid carcinoma with late-onset distant metastases. ( 29118988 )	Tsoli M....Kaltsas G.	2017
27	Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases. ( 29344163 )	Wang P....Chen G.	2017
28	Novel association of MEN1 gene mutations with parathyroid carcinoma. ( 28693130 )	Cinque L....Guarnieri V.	2017
29	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. ( 28751227 )	Christakis I....Zafereo M.	2017
30	The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report. ( 29047366 )	Takada D....Yanagita M.	2017
31	Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. ( 28011856 )	Fountas A....Tsatsoulis A.	2017
32	A nationwide study on parathyroid carcinoma. ( 28362521 )	RyhAonen E.M....Schalin-JAontti C.	2017
33	Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. ( 28427885 )	Silva-Figueroa A.M....Perrier N.D.	2017
34	Nonfunctional double parathyroid carcinoma with incidental thyroid micropapillary carcinoma: a rare case. ( 28979642 )	Dikmen K....Taneri F.	2017
35	Parathyroid Carcinoma in Patients that Have Undergone Surgery for Primary Hyperparathyroidism. ( 28882960 )	LibA!nskA1 P....Bobek V.	2017
36	Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. ( 28881068 )	Cardoso L....Thakker R.V.	2017
37	Non-functioning parathyroid carcinoma: a case report. ( 28726134 )	Suganuma N....Masuda M.	2017
38	Acute pancreatitis as an initial manifestation of parathyroid carcinoma: A case report and literature review. ( 29095277 )	Gao Y....Fang L.	2017
39	Parathyroid carcinoma occurred in two glands in multiple endocrine neoplasia 1: a report on a rare case. ( 29225207 )	Omi Y....Okamoto T.	2017
40	Spontaneous bilateral quadriceps tendon rupture revealing a parathyroid carcinoma. ( 28115266 )	Benameur H....Cambon-Binder A.	2017
41	Oncologic progress for the treatment of parathyroid carcinoma is needed. ( 27753088 )	Christakis I....Perrier N.D.	2016
42	Parathyroid carcinoma. ( 26771263 )	Goswamy J....Simo R.	2016
43	Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. ( 27609904 )	Nam M....Shin J.H.	2016
44	Intrathyroidal parathyroid carcinoma. A case report and review of literature. ( 26588997 )	Tejera HernA!ndez A.A....HernA!ndez HernA!ndez J.R.	2016
45	Association of parathyroid carcinoma and thyroid disorders: A clinical review. ( 27744598 )	CampennA- A....Baldari S.	2016
46	Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. ( 27250989 )	Hu Y....Zhao Y.	2016
47	Parathyroid carcinoma with contralateral subcutaneous and breast recurrences: A rare presentation. ( 26685878 )	Agarwal S....Gandhi A.K.	2016
48	Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. ( 27679651 )	Mele M....Christiansen P.	2016
49	18F-FDG PET/CT Osteometabolic Activity in Metastatic Parathyroid Carcinoma. ( 27276208 )	do Vale R.H....de Menezes M.R.	2016
50	Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. ( 26939543 )	Xue S....Chen X.	2016

Sources

Genes for Parathyroid Carcinoma

Genes related to Parathyroid Carcinoma (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CDC73	Cell Division Cycle 73	Protein Coding	1432.84	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative somatic mutation ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	12434154 20301744 14585940 (more) 16720667 15613436 14715834 15531515 15580289 17555500 16357559 17314275 19926710 14585940 17468190 18987311 16931959 19017757 15475453 12960210 18217513 19148484 18338208 19107770 16116486 15719375 16964291 16720667 18080135 17592260 15731573 20052758 17639063 19522828 18684024 16817812 19906718 17490066 20026646 16728578 17468290 18436011
2	CASR	Calcium Sensing Receptor	Protein Coding	41.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14694525 9543122 16765016
3	PTH	Parathyroid Hormone	Protein Coding	39.89	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10396361 1609615
4	CCND1	Cyclin D1	Protein Coding	37.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8626826 10229506 14694525 (more) 7906387 19373510 15105644 7621424
5	MEN1	Menin 1	Protein Coding	34.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	19491073 10396361
6	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	22.55	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	UCHL1	Ubiquitin C-Terminal Hydrolase L1	Protein Coding	21.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	LGALS3	Galectin 3	Protein Coding	21.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	RET	Ret Proto-Oncogene	Protein Coding	20.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	8616528

Sources

Variations for Parathyroid Carcinoma

ClinVar genetic disease variations for Parathyroid Carcinoma:

⁶

(show top 50) (show all 410)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	CDC73	NM_024529.4(CDC73): c.679_680insAG (p.Arg227Lysfs)	insertion	Pathogenic	rs80356649	GRCh37	Chromosome 1, 193111146: 193111147
2	CDC73	NM_024529.4(CDC73): c.679_680insAG (p.Arg227Lysfs)	insertion	Pathogenic	rs80356649	GRCh38	Chromosome 1, 193142016: 193142017
3	CDC73	NM_024529.4(CDC73): c.128G> A (p.Trp43Ter)	single nucleotide variant	Pathogenic	rs121434263	GRCh37	Chromosome 1, 193091458: 193091458
4	CDC73	NM_024529.4(CDC73): c.128G> A (p.Trp43Ter)	single nucleotide variant	Pathogenic	rs121434263	GRCh38	Chromosome 1, 193122328: 193122328
5	CDC73	NM_024529.4(CDC73): c.162C> G (p.Tyr54Ter)	single nucleotide variant	Pathogenic	rs121434265	GRCh37	Chromosome 1, 193094272: 193094272
6	CDC73	NM_024529.4(CDC73): c.162C> G (p.Tyr54Ter)	single nucleotide variant	Pathogenic	rs121434265	GRCh38	Chromosome 1, 193125142: 193125142
7	CDC73	CDC73, 1-BP INS, 373A	insertion	Pathogenic
8	CDC73	CDC73, 4-BP DEL, 685AGAG	deletion	Pathogenic
9	CDC73	NM_024529.4(CDC73): c.85delG (p.Glu29Serfs)	deletion	Pathogenic	rs587776560	GRCh37	Chromosome 1, 193091415: 193091415
10	CDC73	NM_024529.4(CDC73): c.85delG (p.Glu29Serfs)	deletion	Pathogenic	rs587776560	GRCh38	Chromosome 1, 193122285: 193122285
11	CDC73	NM_024529.4(CDC73): c.13_30del18 (p.Leu5_Gln10del)	deletion	Pathogenic	rs587776561	GRCh37	Chromosome 1, 193091343: 193091360
12	CDC73	NM_024529.4(CDC73): c.13_30del18 (p.Leu5_Gln10del)	deletion	Pathogenic	rs587776561	GRCh38	Chromosome 1, 193122213: 193122230
13	CDC73	NM_024529.4(CDC73): c.766_767delGT (p.Val256Lysfs)	deletion	Pathogenic	rs80356650	GRCh37	Chromosome 1, 193117033: 193117034
14	CDC73	NM_024529.4(CDC73): c.766_767delGT (p.Val256Lysfs)	deletion	Pathogenic	rs80356650	GRCh38	Chromosome 1, 193147903: 193147904
15	CDC73	NM_024529.4(CDC73): c.*12C> A	single nucleotide variant	Likely benign	rs193025205	GRCh37	Chromosome 1, 193219854: 193219854
16	CDC73	NM_024529.4(CDC73): c.*12C> A	single nucleotide variant	Likely benign	rs193025205	GRCh38	Chromosome 1, 193250724: 193250724
17	CDC73	NM_024529.4(CDC73): c.33C> T (p.Tyr11=)	single nucleotide variant	Benign/Likely benign	rs150951102	GRCh37	Chromosome 1, 193091363: 193091363
18	CDC73	NM_024529.4(CDC73): c.33C> T (p.Tyr11=)	single nucleotide variant	Benign/Likely benign	rs150951102	GRCh38	Chromosome 1, 193122233: 193122233
19	CDC73	NM_024529.4(CDC73): c.131+4A> G	single nucleotide variant	Uncertain significance	rs878855089	GRCh37	Chromosome 1, 193091465: 193091465
20	CDC73	NM_024529.4(CDC73): c.131+4A> G	single nucleotide variant	Uncertain significance	rs878855089	GRCh38	Chromosome 1, 193122335: 193122335
21	CDC73	NM_024529.4(CDC73): c.687_688dupAG (p.Val230Glufs)	duplication	Pathogenic	rs878855090	GRCh37	Chromosome 1, 193111154: 193111155
22	CDC73	NM_024529.4(CDC73): c.687_688dupAG (p.Val230Glufs)	duplication	Pathogenic	rs878855090	GRCh38	Chromosome 1, 193142024: 193142025
23	CDC73	NM_024529.4(CDC73): c.787C> T (p.Arg263Cys)	single nucleotide variant	Uncertain significance	rs878855091	GRCh37	Chromosome 1, 193117054: 193117054
24	CDC73	NM_024529.4(CDC73): c.787C> T (p.Arg263Cys)	single nucleotide variant	Uncertain significance	rs878855091	GRCh38	Chromosome 1, 193147924: 193147924
25	CDC73	NM_024529.4(CDC73): c.840G> A (p.Leu280=)	single nucleotide variant	Likely benign	rs10921320	GRCh38	Chromosome 1, 193150315: 193150315
26	CDC73	NM_024529.4(CDC73): c.840G> A (p.Leu280=)	single nucleotide variant	Likely benign	rs10921320	GRCh37	Chromosome 1, 193119445: 193119445
27	CDC73	NM_024529.4(CDC73): c.1032T> G (p.Val344=)	single nucleotide variant	Benign/Likely benign	rs148612206	GRCh37	Chromosome 1, 193181196: 193181196
28	CDC73	NM_024529.4(CDC73): c.1032T> G (p.Val344=)	single nucleotide variant	Benign/Likely benign	rs148612206	GRCh38	Chromosome 1, 193212066: 193212066
29	CDC73	NM_024529.4(CDC73): c.1185A> G (p.Gln395=)	single nucleotide variant	Benign	rs116358657	GRCh37	Chromosome 1, 193202153: 193202153
30	CDC73	NM_024529.4(CDC73): c.1185A> G (p.Gln395=)	single nucleotide variant	Benign	rs116358657	GRCh38	Chromosome 1, 193233023: 193233023
31	CDC73	NM_024529.4(CDC73): c.1193A> T (p.Gln398Leu)	single nucleotide variant	Uncertain significance	rs878855088	GRCh37	Chromosome 1, 193202161: 193202161
32	CDC73	NM_024529.4(CDC73): c.1193A> T (p.Gln398Leu)	single nucleotide variant	Uncertain significance	rs878855088	GRCh38	Chromosome 1, 193233031: 193233031
33	CDC73	NM_024529.4(CDC73): c.1333G> A (p.Val445Ile)	single nucleotide variant	Uncertain significance	rs368442389	GRCh38	Chromosome 1, 193236272: 193236272
34	CDC73	NM_024529.4(CDC73): c.1333G> A (p.Val445Ile)	single nucleotide variant	Uncertain significance	rs368442389	GRCh37	Chromosome 1, 193205402: 193205402
35	CDC73	NM_024529.4(CDC73): c.-10G> T	single nucleotide variant	Benign/Likely benign	rs188082584	GRCh37	Chromosome 1, 193091321: 193091321
36	CDC73	NM_024529.4(CDC73): c.-10G> T	single nucleotide variant	Benign/Likely benign	rs188082584	GRCh38	Chromosome 1, 193122191: 193122191
37	CDC73	NM_024529.4(CDC73): c.-4dupG	duplication	Conflicting interpretations of pathogenicity	rs545666726	GRCh37	Chromosome 1, 193091327: 193091327
38	CDC73	NM_024529.4(CDC73): c.-4dupG	duplication	Conflicting interpretations of pathogenicity	rs545666726	GRCh38	Chromosome 1, 193122197: 193122197
39	CDC73	NM_024529.4(CDC73): c.-186C> G	single nucleotide variant	Uncertain significance	rs886045710	GRCh37	Chromosome 1, 193091145: 193091145
40	CDC73	NM_024529.4(CDC73): c.-186C> G	single nucleotide variant	Uncertain significance	rs886045710	GRCh38	Chromosome 1, 193122015: 193122015
41	CDC73	NM_024529.4(CDC73): c.-143G> C	single nucleotide variant	Uncertain significance	rs778446879	GRCh37	Chromosome 1, 193091188: 193091188
42	CDC73	NM_024529.4(CDC73): c.-143G> C	single nucleotide variant	Uncertain significance	rs778446879	GRCh38	Chromosome 1, 193122058: 193122058
43	CDC73	NM_024529.4(CDC73): c.-121G> A	single nucleotide variant	Uncertain significance	rs886045711	GRCh37	Chromosome 1, 193091210: 193091210
44	CDC73	NM_024529.4(CDC73): c.-121G> A	single nucleotide variant	Uncertain significance	rs886045711	GRCh38	Chromosome 1, 193122080: 193122080
45	CDC73	NM_024529.4(CDC73): c.-95G> A	single nucleotide variant	Likely benign	rs143969598	GRCh37	Chromosome 1, 193091236: 193091236
46	CDC73	NM_024529.4(CDC73): c.-95G> A	single nucleotide variant	Likely benign	rs143969598	GRCh38	Chromosome 1, 193122106: 193122106
47	CDC73	NM_024529.4(CDC73): c.659T> C (p.Val220Ala)	single nucleotide variant	Uncertain significance	rs886045713	GRCh37	Chromosome 1, 193111126: 193111126
48	CDC73	NM_024529.4(CDC73): c.659T> C (p.Val220Ala)	single nucleotide variant	Uncertain significance	rs886045713	GRCh38	Chromosome 1, 193141996: 193141996
49	CDC73	NM_024529.4(CDC73): c.*94A> G	single nucleotide variant	Likely benign	rs547969893	GRCh37	Chromosome 1, 193219936: 193219936
50	CDC73	NM_024529.4(CDC73): c.*94A> G	single nucleotide variant	Likely benign	rs547969893	GRCh38	Chromosome 1, 193250806: 193250806

Sources

Expression for Parathyroid Carcinoma

Search GEO for disease gene expression data for Parathyroid Carcinoma.

Sources

Pathways for Parathyroid Carcinoma

Pathways related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ⁴	11.97	CALCA RET UCHL1
2	Hepatitis C and Hepatocellular Carcinoma ¹	10.86	CCND1 UCHL1
3	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.61	CALCA PTH
4	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²²	10.21	CCND1 PTH

Sources

GO Terms for Parathyroid Carcinoma

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	neuronal cell body	GO:0043025	9.26	CALCA CASR RET UCHL1
2	axon	GO:0030424	8.92	CALCA CASR RET UCHL1

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of transcription by RNA polymerase II	GO:0000122	9.73	CCND1 CDC73 MEN1 PTH
2	response to drug	GO:0042493	9.67	CCND1 PTH RET
3	negative regulation of epithelial cell proliferation	GO:0050680	9.54	CDC73 MEN1
4	cellular response to glucose stimulus	GO:0071333	9.52	CASR MEN1
5	response to calcium ion	GO:0051592	9.51	CASR CCND1
6	monocyte chemotaxis	GO:0002548	9.48	CALCA LGALS3
7	beta-catenin-TCF complex assembly	GO:1904837	9.46	CDC73 MEN1
8	response to ischemia	GO:0002931	9.4	CASR UCHL1
9	vasodilation	GO:0042311	9.37	CALCA CASR
10	response to pain	GO:0048265	9.32	CALCA RET
11	positive regulation of calcium ion import	GO:0090280	9.26	CASR LGALS3
12	positive regulation of ossification	GO:0045778	9.16	CALCA PTH
13	cellular calcium ion homeostasis	GO:0006874	9.13	CALCA CASR PTH
14	response to fibroblast growth factor	GO:0071774	8.62	CASR PTH

Sources

Sources for Parathyroid Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia